Copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2004
I read with interest and some bewilderment the recent post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study.1 The report concluded that baseline blood pressure (BP), especially systolic blood pressure (SBP), was a strong predictor of renal outcomes and that those with the highest baseline pulse pressure (PP) had the highest risk for nephropathy progression.1
Onuigbo MAC. Achieved vs Initial Blood Pressure in Predicting Renal Outcomes. Arch Intern Med. 2004;164(2):223. doi:10.1001/archinte.164.2.223-a
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: